In:
Arteriosclerosis, Thrombosis, and Vascular Biology, Ovid Technologies (Wolters Kluwer Health), Vol. 22, No. 9 ( 2002-09)
Abstract:
Objective— We investigated the effects of statin compared with the American Heart Association (AHA) Step I Diet on lipoproteins, vasomotor function, tumor necrosis factor (TNF)-α, and serological markers of plaque stability. Furthermore, we investigated the mechanism of regulation suggested by experimental studies. Methods and Results— For 14 weeks, we administered AHA diet+placebo and AHA diet+simvastatin (20 mg daily) to 31 and 32 randomly selected patients with coronary artery disease, respectively. Compared with diet alone, simvastatin significantly improved the percent flow-mediated dilator response to hyperemia from 3.37±2.28% to 5.89±2.35% ( P 〈 0.001) and lowered plasma levels of C-reactive protein from 0.48 to 0.10 mg/dL ( P 〈 0.001), TNF-α from 3.38 to 2.79 pg/mL ( P 〈 0.001), total matrix metalloproteinase (MMP)-9 from 36 to 28 ng/mL ( P =0.006), and tissue inhibitor of matrix metalloproteinase-1 from 80±30 to 74±23 ng/mL ( P =0.041), and simvastatin lowered to a greater extent MMP-9 activity (from 71 to 52 ng/mL, P =0.006) and MMP-9 activity/tissue inhibitor of matrix metalloproteinase-1 ratios ( P =0.018), although this difference did not reach statistical significance. There were significant correlations between the degree of changes in TNF-α and the degree of changes in MMP-9 activity ( r =0.424, P =0.016). However, no significant correlations between lipoprotein levels or flow-mediated dilation percentages and levels of plaque stability markers were determined (−0.208≤ r ≤0.243). Conclusions— Simvastatin reduced serological markers of inflammation and plaque stability, independent of lipoprotein changes.
Type of Medium:
Online Resource
ISSN:
1079-5642
,
1524-4636
DOI:
10.1161/01.ATV.0000030997.02059.BB
Language:
English
Publisher:
Ovid Technologies (Wolters Kluwer Health)
Publication Date:
2002
detail.hit.zdb_id:
1494427-3
